Needham analyst Serge Belanger has maintained their bullish stance on VRDN stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Serge Belanger has given his Buy rating due to a combination of factors that highlight Viridian Therapeutics’ promising future. The company has recently completed the enrollment for its Phase 3 REVEAL trials, which are critical for evaluating the subcutaneous version of their drug, VRDN-003. The anticipated results from these trials are expected in the first and second quarters of 2026, setting the stage for a Biologics License Application (BLA) filing by the end of 2026.
Additionally, Viridian Therapeutics has successfully filed a BLA for their drug veli, with the FDA’s acceptance anticipated by late December or early January. This could potentially lead to a Priority Review and a possible approval by mid-2026. Furthermore, the company has bolstered its financial position through recent financing transactions, securing up to $889 million, which, combined with their existing cash reserves, positions them well for future developments. These strategic moves and financial stability underpin Belanger’s optimistic outlook and Buy rating for Viridian Therapeutics.
According to TipRanks, Belanger is a 4-star analyst with an average return of 8.4% and a 47.60% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Cormedix, and Amphastar Pharmaceuticals.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $42.00 price target.